Match Document Document Title
7592004 Stable lyophilized pharmaceutical formulation of IgG antibodies  
This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG...
7592007 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies  
Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4...
7589182 Anti-sulfotyrosine antibodies  
The invention provides anti-sulfotyrosine specific antibodies capable of detecting and isolating polypeptides that are tyrosine-sulfated. The sulfotyrosine antibodies and antibody fragments of the...
7589181 Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use  
Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain...
7588760 Antagonists specific for denatured collagen and methods of using same  
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple...
7585501 Compositions and methods for treating kidney disease  
The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to...
7585502 Mammalian CX3C chemokine antibodies  
Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using...
7585953 Antibodies specific for TAT285-1  
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
7585500 Fully human monoclonal antibodies to IL-13  
The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies...
7582299 Cripto-specific antibodies  
The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies...
7582297 Methods of treating respiratory conditions  
The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the...
7582294 Medicament for treating prostate diseases  
A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared...
7582296 Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof  
The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor...
7579000 Tissue factor targeted antibodies as anticoagulants  
This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF...
7579447 Antibodies against LLG polypeptides of the triacylglycerol lipase family  
Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the...
7578999 Antibodies specific for sclerostin  
A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. In...
7579448 Purification of microbial cell fermentation homogenates  
A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the...
7579187 Anti-A33 antibody  
The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the...
7575746 Modified human IGF-IR antibodies  
The present invention relates to antibodies, which are directed to the human IGF-1 receptor (IGF-1R) and are to be administered for the treatment of cancer. The antibodies of the present invention...
7572441 Media and method for treating pathological syndrome  
A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and...
7572443 Anti-PECAM therapy for metastasis suppression  
The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases.
7572448 Combined cancer treatment methods using selected antibodies to aminophospholipids  
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for...
7572442 Selected antibody compositions for binding to aminophospholipids  
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for...
7569674 Autophilic antibodies  
Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can...
7569673 Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors  
The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody...
7566453 Methods for treating melanomas  
A therapeutic agent for myeloma comprising a combined use of a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody. Thus, a therapeutic agent for myeloma comprising anti-IL-6 receptor...
7563874 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins  
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof...
7563882 Polynucleotides encoding antibodies that bind to the C35 polypeptide  
The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human...
7563445 CD40 binding molecules and CTL peptides for treating tumors  
Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor...
7563442 Antibodies to CD40 and methods of treating cancer and enhancing immune responses  
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
7563438 FGF homologs and antibodies thereto  
The present invention relates to antibodies and fragments thereof, polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides...
7563443 Monovalent anti-CD40L antibody polypeptides and compositions thereof  
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential...
7563582 Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction  
The invention relates to processes for identifying chemical compounds which are capable of modulating the interaction between VASP and zyxin. VASP or a VASP derivative and zyxin or a zyxin...
7563441 Anti-P-selectin antibodies  
This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind...
7560095 Cancer specific monoclonal antibodies  
Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of...
7556804 Anti-HGF-R antibodies and their use  
The present invention relates to monoclonal antibodies which recognize the chain of the HFG receptor with the agonist activity of the natural ligand. The invention also relates to the hybridoma...
7556803 Method for treating multiple myeloma  
The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by...
7553485 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof  
The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R)...
7553486 Anti-VEGF treatment for radiation-induced vasculopathy  
An anti-VEGF method for treating undesirable conditions resulting from radiation-induced vasculopathy. In a specific application, the method is applied to these undesirable conditions found in an eye.
7553484 Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule  
The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably,...
7553488 Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions  
The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the...
7550144 Prion inhibition  
The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection,...
7550568 Monoclonal antibodies to human high molecular weight-melanoma associated antigen  
The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.
7547437 Method of treating fibrosis  
Materials and methods for treating fibrosis in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3...
7547438 CD40-binding activating antibodies  
Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance...
7547768 Anti-TAT 113 antibodies  
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
7541440 Chimeric, human and humanized anti-granulocyte antibodies and methods of use  
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations...
7541030 Antibodies for identifying and/or isolating at least one cell population which is selected from the group comprising haematopoietic stem cells, neuronal stem cells, neuronal precursor cells, mesenchymal stem cells and mesenchymal precursor cells  
The invention relates to monoclonal antibodies, or fragments thereof, for isolating and/or identifying at least one cell population which is selected from the group comprising haematopoietic stem...
7541029 Anti-rhesus D monoclonal antibodies  
The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan...
7537757 Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II  
A method of facilitating vascular growth in cardiac muscle of a subject in need of such treatment comprises inhibiting EMAP II activity in said subject by an amount effective to stimulate vascular...